Editorial Jetcityimage / ISTOCK via Getty Images
Eli Lilly’s (Nyse: lly) Eloralinetide experimental obesity therapy caused up to 11% weight loss over 12 weeks in a start -up trial, according to data published Friday before a conference on health care next week.
Quoting a summary published before
